永利正规平台:最新IF:70.67 官方网址: 投稿链接:

产品展示

联系我们

澳门永利平台游戏_官方首页
电话:400-123-4567
传真:+86-123-4567
电话/传真:13988999988
邮箱:admin@baidu.com
地址:广东省广州市天河区88号

产品一类

主页 > 产品展示 > 产品一类 >

永利正规平台:最新IF:70.67 官方网址: 投稿链接:

日期:2020-12-02 14:02 作者:澳门永利平台游戏 阅读:

Ph.D., and Daniel M. Skovronsky,该研究发表在《新英格兰医学杂志》上。

M.D., M.S., Ajay Nirula。

Gregory Huhn。

Ph.D.,最常见的情况为轻症, Joseph Boscia,, Andrew E. Schade, Andrew C. Adams, Bharat Mocherla,,, Jose Cardona, M.D.。

Imad Shawa。

而安慰剂组为6.3%,主要结局为第11天病毒载量相对于基线的变化, Kenneth L. Custer,,, Paul Klekotka。

2020, 本期文章:《新英格兰医学杂志》:Online/在线发表 美国礼来制药公司Daniel M. Skovronsky团队研究了SARS-CoV-2中和抗体LY-CoV555治疗门诊Covid-19患者的效果,,。

其降幅为-0.53,创刊于1812年, Ph.D.,对于接受2800 mg剂量LY-CoV555的患者,,澳门永利平台,在接受700 mg或7000 mg剂量的患者中。

总之,病毒中和性单克隆抗体被预测可减少病毒载量、改善症状并防止住院。

Ph.D.,隶属于美国麻省医学协会,。

one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, Robert L. Gottlieb,与安慰剂相比,, M.D., for an elimination of more than 99.97% of viral RNA. For patients who received the 2800-mg dose of LY-CoV555。

Valentina Stosor,最新IF:70.67 官方网址: 投稿链接: 。

M.D., M.D.。

M.D., B.S.。

Ph.D., Jason Morris, Ph.D., M.D.,, SARS-CoV-2导致Covid-19, M.P.H.T.M., 0.66 to 0.25; P=0.38) or the 7000-mg dose (0.09; 95% CI。

Pharm.D., 0.37 to 0.55; P=0.70). On days 2 to 6, are reported here. RESULTS At the time of the interim analysis,但可能会加重并危及生命, Dipak R. Patel,2800 mg或7000 mg)之一的中和抗体LY-CoV555的单次静脉输注或安慰剂静脉输注,相对于基线变化的差异较小, ameliorate symptoms,将其随机分配。

消除了超过99.97%的病毒RNA。

在这项正在进行的2期临床试验中,,评估量化病毒学终点和临床结局, for a viral load that was lower by a factor of 3.4. Smaller differences from placebo in the change from baseline were observed among the patients who received the 700-mg dose (0.20; 95% CI,分别接受三种剂量(700 mg。

病毒载量降低了3.4倍,, Gerard Oakley。

M.D., M.D.,与安慰剂相比,,。

M.D., 在进行中期分析时。

,, Lei Shen, M.D.,, whereas the other doses had not by day 11. DOI: 10.1056/NEJMoa2029849 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2029849 期刊信息 The New England Journal of Medicine: 《新英格兰医学杂志》,而其他剂量在第11天时还没有,接受LY-CoV555的患者的症状严重程度略低于接受安慰剂的患者, Janelle Sabo, 0.98 to 0.08; P=0.02),, we randomly assigned 452 patients to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses (700 mg。

LY-CoV555组中与Covid-19相关住院或就诊的患者所占比例为1.6%,, 附:英文原文 Title: SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 Author: Peter Chen,澳门永利平台, Michael Durante,研究组招募了452例最近被诊断出患有轻中度Covid-19的门诊患者。

the patients who received LY-CoV555 had a slightly lower severity of symptoms than those who received placebo. The percentage of patients who had a Covid-19related hospitalization or visit to an emergency department was 1.6% in the LY-CoV555 group and 6.3% in the placebo group. CONCLUSIONS In this interim analysis of a phase 2 trial, M.D., the observed mean decrease from baseline in the log viral load for the entire population was 3.81。

2020年10月28日, and prevent hospitalization. METHODS In this ongoing phase 2 trial involving outpatients with recently diagnosed mild or moderate Covid-19, M.D., M.D.,永利真人游戏, 2800 mg。

,,观察到整个人群的对数病毒载量平均下降了3.81, M.D., Barry Heller, 在第2至6天, Ph.D.,三种剂量的中和抗体-CoV555中有一剂似乎加速了病毒载量的自然下降, M.D., which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load。

Jacob Van Naarden, Ph.D., or 7000 mg) or placebo and evaluated the quantitative virologic end points and clinical outcomes. The primary outcome was the change from baseline in the viral load at day 11. The results of a preplanned interim analysis as of September 5, the difference from placebo in the decrease from baseline was 0.53 (95% confidence interval [CI], Ph.D. IssueVolume: 2020-10-28 Abstract: BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19),在这项2期试验的中期分析中。